These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3165675)

  • 1. Myelodysplastic relapse of de novo acute myeloid leukaemia with trilineage myelodysplasia.
    Ng JP; Pati A; Strevens MJ; Swart S
    Br J Haematol; 1988 Aug; 69(4):578. PubMed ID: 3165675
    [No Abstract]   [Full Text] [Related]  

  • 2. Myelodysplastic relapse of de novo acute myeloid leukaemia with trilineage myelodysplasia: a previously unrecognized correlation.
    Brito-Babapulle F; Catovsky D; Galton DA
    Br J Haematol; 1988 Apr; 68(4):411-5. PubMed ID: 3163932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term remission of acute myeloid leukaemia with trilineage myelodysplasia treated solely with low dose cytarabine.
    Jack FR; Summerfield GP
    Clin Lab Haematol; 1994 Jun; 16(2):197-200. PubMed ID: 7955930
    [No Abstract]   [Full Text] [Related]  

  • 4. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
    Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
    Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E
    Br J Haematol; 2007 Aug; 138(4):555-7. PubMed ID: 17593249
    [No Abstract]   [Full Text] [Related]  

  • 6. Remission with morphological myelodysplasia in de novo acute myeloid leukaemia: implications for early relapse.
    Nagai K; Matsuo T; Atogami S; Moriuchi Y; Yoshida Y; Kuriyama K; Tomonaga M
    Br J Haematol; 1992 May; 81(1):33-9. PubMed ID: 1520622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high-risk myelodysplastic syndrome.
    Warny M; Helby J; Sengeløv H; Nordestgaard BG; Birgens H; Bojesen SE
    Eur J Haematol; 2019 Mar; 102(3):218-226. PubMed ID: 30427547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo acute myelogenous leukemia with trilineage myelodysplasia associated with t(8;21)(q22;q22).
    Fujisawa S; Togawa J; Tanaka M; Koharazawa H; Aoba M; Fujita H; Murata T; Kanamori H; Matsuzaki M; Mohri H; Ishigatsubo Y
    Intern Med; 1999 Jul; 38(7):607-11. PubMed ID: 10435370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
    Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
    Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with low dose Ara-C in de novo acute myeloid leukemia with trilineage myelodysplasia.
    Kawano F; Nishimura Y; Tsukamoto A; Satoh M; Sanada I; Shido T
    Int J Hematol; 1992 Feb; 55(1):101-2. PubMed ID: 1581580
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-term remissions in postmyelodysplasia acute myeloblastic leukemia].
    Olavarría E; Román A; Prieto E; Cabello A; Sánchez Fayos J
    Rev Clin Esp; 1994 Jun; 194(6):511-2. PubMed ID: 8079028
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.
    Tholouli E; Liakopoulou E; Greenfield HM; Shaw BE; Tauro S; Byrne JL; Dennis M; Burthem J; Lucas GS; Craddock C; Russell NH; Liu Yin JA
    Br J Haematol; 2008 Jun; 142(2):318-20. PubMed ID: 18492100
    [No Abstract]   [Full Text] [Related]  

  • 13. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
    Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
    Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
    Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
    Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
    Bär BM; de Witte T; de Pauw BE; Haanen C
    Neth J Med; 1990 Feb; 36(1-2):19-24. PubMed ID: 2314517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment strategy for de novo AML with trilineage myelodysplasia].
    Kuriyama K
    Rinsho Ketsueki; 1994 Mar; 35(3):267-71. PubMed ID: 8158847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very-low-dose cytarabine for myelodysplastic syndromes and acute myeloid leukaemia in the elderly.
    Worsley A; Mufti GJ; Copplestone JA; Oscier DG; Hamblin TJ
    Lancet; 1986 Apr; 1(8487):966. PubMed ID: 2871254
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia.
    Brito-Babapulle F; Catovsky D; Galton DA
    Br J Haematol; 1987 Aug; 66(4):445-50. PubMed ID: 3478074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
    Zeidan AM; Smith BD; Carraway HE; Gojo I; DeZern A; Gore SD
    Br J Haematol; 2017 Jan; 176(2):241-247. PubMed ID: 27790720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.